Ronna Sue Cohen cut its holdings in CVS Health Corp (NYSE:CVS) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,110 shares of the pharmacy operator’s stock after selling 762 shares during the period. CVS Health makes up 2.9% of Ronna Sue Cohen’s portfolio, making the stock its 8th largest position. Ronna Sue Cohen’s holdings in CVS Health were worth $4,140,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of CVS. Beach Investment Management LLC. bought a new position in shares of CVS Health during the second quarter valued at about $2,224,000. Sentry Investments Corp. raised its stake in shares of CVS Health by 1.0% during the second quarter. Sentry Investments Corp. now owns 5,519,100 shares of the pharmacy operator’s stock valued at $444,067,000 after acquiring an additional 57,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in shares of CVS Health by 48.0% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 19,189 shares of the pharmacy operator’s stock valued at $1,544,000 after acquiring an additional 6,226 shares during the last quarter. Artemis Investment Management LLP bought a new position in shares of CVS Health during the second quarter valued at about $7,348,000. Finally, Sequoia Financial Advisors LLC raised its stake in shares of CVS Health by 0.8% during the second quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock valued at $515,000 after acquiring an additional 53 shares during the last quarter. 84.12% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have recently commented on the stock. Bank of America assumed coverage on shares of CVS Health in a research note on Tuesday, February 27th. They set a “buy” rating and a $91.00 price objective for the company. Citigroup set a $77.00 price objective on shares of CVS Health and gave the company a “neutral” rating in a research note on Tuesday, February 13th. Leerink Swann set a $85.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research note on Friday, February 9th. Robert W. Baird lowered their price objective on shares of CVS Health from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, February 9th. Finally, Royal Bank of Canada set a $89.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research note on Thursday, February 8th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $87.03.
CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04. The business had revenue of $48.39 billion for the quarter, compared to analysts’ expectations of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.71 earnings per share. analysts anticipate that CVS Health Corp will post 6.37 EPS for the current year.
In other CVS Health news, EVP Helena Foulkes sold 19,965 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $71.04, for a total value of $1,418,313.60. Following the sale, the executive vice president now owns 65,072 shares in the company, valued at $4,622,714.88. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/cvs-health-corp-cvs-shares-sold-by-ronna-sue-cohen.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.